First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
EAST SETAUKET, NY--(Marketwired - Jan 4, 2017) - Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced the publication online of Phase 1 results of its novel anti-cancer compound in Clinical Cancer Research, entitled "Safety, tolerability, and …